Sangamo, Prevail Therapeutics ink deal for evaluating AAV capsids
Sangamo Therapeutics, a genomic medicine company, has entered an evaluation and option agreement with Prevail Therapeutics, an Eli Lilly subsidiary, for novel engineered capsids. The deal allows Prevail Therapeutics to evaluate Sangamo Therapeutics’ proprietary adeno-associated virus (AAV) capsids for potential use in various neurological targets. The capsids, produced through Sangamo Therapeutics’ AAV capsid engineering platform […]